Oncorus, Inc. financial data

Industry
Pharmaceutical Preparations
Location
4 Corporate Drive, Andover, MA
State of incorporation
DE
Fiscal year end
December 31

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 294 % -69.5%
Debt-to-equity 123 % +183%
Return On Equity -134 % -167%
Return On Assets -60.1 % -71.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.1M shares +0.47%
Common Stock, Shares, Outstanding 26.1M shares +0.82%
Entity Public Float 25.9M USD -89.3%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 26.1M shares +0.89%
Weighted Average Number of Shares Outstanding, Diluted 26.1M shares +0.89%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 52.9M USD +8.63%
General and Administrative Expense 20.9M USD -1.51%
Operating Income (Loss) -88.4M USD -26.4%
Nonoperating Income (Expense) -2.12M USD -2507%
Net Income (Loss) Attributable to Parent -90.5M USD -29.6%
Earnings Per Share, Basic -3.48 USD/shares -71%
Earnings Per Share, Diluted -3.48 USD/shares -71%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 21.2M USD -71.9%
Assets, Current 46.7M USD -54.5%
Property, Plant and Equipment, Net 34.9M USD +18.2%
Operating Lease, Right-of-Use Asset 24.2M USD -39.7%
Other Assets, Noncurrent 580K USD -31.7%
Assets 110M USD -37.8%
Accounts Payable, Current 2.76M USD -22.9%
Accrued Liabilities, Current 6.62M USD -3.81%
Liabilities, Current 31.1M USD +156%
Operating Lease, Liability, Noncurrent 47.5M USD -4.8%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 78.6M USD +26.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -24K USD +40%
Retained Earnings (Accumulated Deficit) -303M USD -42.6%
Stockholders' Equity Attributable to Parent 31.1M USD -72.8%
Liabilities and Equity 110M USD -37.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.4M USD +25.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 13M USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 26.1M shares +0.82%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.49M USD +82.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.7M USD -68.8%
Deferred Tax Assets, Valuation Allowance 76M USD +43%
Cash and Cash Equivalents, Period Increase (Decrease) -25.2M USD -160%
Deferred Tax Assets, Gross 88.7M USD +34.8%
Operating Lease, Liability 48.7M USD -5.6%
Payments to Acquire Property, Plant, and Equipment 73K USD -96.1%
Lessee, Operating Lease, Liability, to be Paid 81.7M USD -7.84%
Property, Plant and Equipment, Gross 49.7M USD +69.2%
Operating Lease, Liability, Current 1.19M USD -29.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.64M USD -42.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 32.9M USD -11%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.15M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 47.9M USD +15%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.3M USD 0%
Operating Lease, Payments 1.21M USD -19.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.1M USD +88.5%
Deferred Tax Assets, Net of Valuation Allowance 12.7M USD +0.43%
Share-based Payment Arrangement, Expense 6.7M USD -9.25%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%